KAREN CHU, N.P.
Nursing at Mott St, New York, NY
License number
New York F382400
Category
Nursing
Type
Licensed Practical Nurse
Address
Address
128 Mott St STE 501, New York, NY 10013
Phone
(212) 227-8588
Personal information
See more information about KAREN CHU at radaris.comName
Address
Phone
474 Ridgebury Rd, Slate Hill, NY 10973
7123 163Rd St, Fresh Meadows, NY 11365
73 Richbell Rd, White Plains, NY 10605
105 E 100Th St APT 4B, New York, NY 10029
151 E 83Rd St, New York, NY 10028
Professional information
Vp, Equities It Project/ Program Management, New York At Nomura Securities
Position:
VP, Equities IT Project/ Program Management at Nomura Securities
Location:
Greater New York City Area
Industry:
Investment Banking
Work:
Nomura Securities
- Greater New York City Area since Dec 2009
-
VP, Equities IT Project/ Program Management
Barclays Capital
- Greater New York City Area Sep 2008 - Nov 2009
-
VP, Equity Derivatives Technology
Lehman Brothers
- Greater New York City Area Dec 2004 - Sep 2008
-
VP, Equity Derivatives Technology
Lehman Brothers
- Tokyo, Japan Aug 1999 - Nov 2004
-
AVP, Equity Derivatives Technology
Education:
Imperial College London 1995 - 1999
BEng, Information Systems Engineering
BEng, Information Systems Engineering
Accounting Professional
Location:
Greater New York City Area
Industry:
Accounting
Work:
Johnson & Johnson
Jun 2008 - Feb 2009
-
Business (System) Analyst
Education:
Eastern Michigan University 1996 - 1998
Master, Accounting
Master, Accounting
Director, Clinical Strategy And Execution, Ophthalmology At Regeneron Pharmaceuticals
Position:
Director, Clinical Strategy and Execution, Ophthalmology at Regeneron Pharmaceuticals
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
Regeneron Pharmaceuticals
- Tarrytown, NY since Sep 2012
-
Director, Clinical Strategy and Execution, Ophthalmology
Regeneron Pharmaceuticals
Sep 2003 - Dec 2012
-
Director, Therapeutic Area Project Management
GenVec
Jun 1999 - Aug 2003
-
Associate Director, Clinical Research
Purdue Pharma L.P.
1997 - 1998
-
Clinical Quality Assurance Associate
Education:
Columbia University College of Physicians and Surgeons 1995 - 1996
MS, Human Nutrition California Polytechnic State University-San Luis Obispo 1990 - 1996
BS, Biology
MS, Human Nutrition California Polytechnic State University-San Luis Obispo 1990 - 1996
BS, Biology
Executive Director, Clinical Operations At Apex
Position:
Executive Director, Clinical Operations at APEX
Location:
Greater New York City Area
Industry:
Research
Work:
APEX
-
Executive Director, Clinical Operations
Education:
Rutgers, The State University of New Jersey-New Brunswick 2002
Corporate Vp At Parexel
Position:
Corporate Vice President, Project Leadership Asia Pacific at PAREXEL
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
PAREXEL
since Aug 2002
-
Corporate Vice President, Project Leadership Asia Pacific
Education:
Rutgers, The State University of New Jersey-New Brunswick
Corporate Vp At Parexel
Position:
Vice President, Project Leadership Asia Pacific at PAREXEL
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
PAREXEL
since Aug 2002
-
Vice President, Project Leadership Asia Pacific
Karen Chu, New York NY
Specialties:
Nurse Practitioner
Address:
128 Mott St, New York, NY 10013
Therapeutic Regimen For Treating Cancer
US Patent:
2010030, Dec 2, 2010
Filed:
Aug 12, 2010
Appl. No.:
12/855050
Inventors:
Henrik S. Rasmussen - Arnold MD, US
Karen W. Chu - New York NY, US
Karen W. Chu - New York NY, US
Assignee:
GenVec, Inc. - Gaithersburg MD
International Classification:
A61K 31/7088, A61P 35/00
US Classification:
514 44 R
Abstract:
The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about 1×10to about 4×10particle units (pu) of replication-deficient adenoviral vector, at least once in a therapeutic period comprising up to 10 weeks, whereby the cancer in human is treated. The invention further provides a method of treating a human for multiple tumors, wherein the method comprises contacting a first tumor with a dose of the pharmaceutical composition at least once in a therapeutic period comprising up to about 10 weeks, whereby the human is treated for the first tumor and one or more additional tumors.
Therapeutic Regimen For Treating Cancer
US Patent:
2007016, Jul 19, 2007
Filed:
Apr 2, 2007
Appl. No.:
11/695437
Inventors:
Henrik Rasmussen - Arnold MD, US
Karen Chu - New York NY, US
Karen Chu - New York NY, US
Assignee:
GenVec, Inc. - Gaithersburg MD
International Classification:
A61K 48/00, C12N 15/861
US Classification:
424093200, 435456000, 600001000
Abstract:
The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about 1×10to about 4×10particle units (pu) of replication-deficient adenoviral vector, at least once in a therapeutic period comprising up to 10 weeks, whereby the cancer in human is treated. The invention further provides a method of treating a human for multiple tumors, wherein the method comprises contacting a first tumor with a dose of the pharmaceutical composition at least once in a therapeutic period comprising up to about 10 weeks, whereby the human is treated for the first tumor and one or more additional tumors.
Therapeutic Regimen For Treating Cancer
US Patent:
2003008, May 8, 2003
Filed:
Nov 2, 2001
Appl. No.:
10/001017
Inventors:
Henrik Rasmussen - Arnold MD, US
Karen Chu - New York NY, US
Karen Chu - New York NY, US
Assignee:
GenVec, Inc. - Gaithersburg MD
International Classification:
A01N063/00
US Classification:
424/093100
Abstract:
The present invention provides a method for reducing the size of a tumor in a human comprising (a) directly injecting into the tumor, via multiple injections to different points of the tumor, a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding TNF- operably linked to a promoter, wherein the dose comprises about 1×10to about 4×103 particle units (pu) of replication-deficient adenoviral vector, two or more times over a therapeutic period comprising up to 10 weeks, and (b) administering a dose of ionizing radiation over the duration of the therapeutic period, whereby the size of the tumor is reduced.